Paper - WANFANG MED ONLINE

You Position: Home > Paper

Factors related to clinical relapse in patients with chronic hepatitis B after withdrawal of nucleos(t)ide analogues

( views:88, downloads:76 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 6

DOI:: 10.3760/cma.j.issn.1674-2397.2015.06.014

Key Word:: 肝炎,乙型,慢性;抗病毒药;停药;复发;危险因素;Hepatitis B,chronic;Antiviral agents;Withdrawal;Recurrence;Risk factors

Abstract： Oral anti-viral agents nucleos (t)ide analogues (NAs) are widely used in treatment of chronic hepatitis B (CHB) since they are well-tolerated in most patients.But clinical relapse occurs in a considerable part of patients after the cessation of NAs therapy.This paper reviews factors related to clinical relapse, including time for drug withdrawal, cccDNA level, age, baseline alanine aminotransferase (ALT) and HBV DNA levels, type of NAs, serum level of HBsAg and the immune status of patients.

Reference

[1]梁延秀,江建宁,苏明华,等.核苷（酸）类似物抗乙型肝炎病毒达到治疗终点标准停药后复发的相关因素分析[J].2011,(5).
[2]万谟彬.治疗终点及与停药原则相关的概念和内涵[C].2012.
[3]Hai-Ying Lu,Li-Wei Zhuang,Yan-Yan Yu,etc.Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients[J].2008,(8).
[4]陆海英,庄立伟,于岩岩,等.抗病毒药物对肝组织乙型肝炎病毒共价闭合环状DNA的影响[J].2008,(3).
[5]陈立,李孝楼,甘巧蓉,等.核苷（酸）类似物治疗慢性乙型肝炎停药复发患者的临床特点及其影响因素[J].2013,(11).
[6]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2015更新版）[J].2015,(6).
[7]史萍,蒋龙凤,李军.慢性乙型肝炎患者核苷（酸）类药物停药后复发的相关因素荟萃分析[J].2015,(1).
[8]李德忠,曾勇彬,苏明宽,等.监测HBsAg浓度对HBeAg阳性的慢性乙型肝炎患者恩替卡韦治疗反应的预测价值[J].2014,(2).
[9]Dengming, He,Shimin, Guo,Wen, Chen,etc.Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.[J].2013,13.
[10]Dienstag JL.Benefits and risks of nucleoside analog therapy for hepatitis B.[J].2009,49(5 Suppl.).
[11]盛秋菊,窦晓光.2015年亚太肝病学会乙型肝炎管理临床实践指南草案解读[J].2015,(9).
[12]Young-Joo, Jin,Kang Mo, Kim,Dong-jun, Yoo,etc.Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients.[J].2012,9.
[13]Pan, Xingfei,Zhang, Ka,Yang, Xiaoan,etc.Relapse Rate and Associated-Factor of Recurrence after Stopping NUCs Therapy with Different Prolonged Consolidation Therapy in HBeAg Positive CHB Patients.[J].2013,8(7).
[14]Hadziyannis,S.J.,Vassilopoulos,D.,Sevastianos,V.,etc.Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J].2012,143(3).
[15]Jiang, Jian-ning,Liang, Yan-xiu,Li, Shi-hua,etc.Residual Amount of HBV DNA in Serum is Related to Relapse in Chronic Hepatitis B Patients After Cessation of Nucleos(t)ide Analogs[J].2015,49(4).
[16]Cristina Pérez-Cameo,Mònica Pons,Rafael Esteban.New therapeutic perspectives in HBV: when to stop NAs[J].2014,34(Supplement).
[17]Patwardhan,V.R.,Sengupta,N.,Bonder,A.,etc.Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides[J].2014,40(7).
[18]Chen,C.-H.,Lu,S.-N.,Hung,C.-H.,etc.The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment[J].2014,61(3).
[19]Huang,Z.-L.,Lu,C.-R.,Gao,Z.-L.,etc.Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients[J].2014,59(1).
[20][Noauthornameavailable].EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J].2012,57(1).
[21]Bao W,Goodman ZD,Manns MP,etc.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.[J].2010,52(5).
[22]Huang X,Chan HL,Zhu M,etc.Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.[J].2011,34(3).
[23]Reijnders JG,Perquin MJ,Zhang N,etc.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.[J].2010,139(2).
[24]Zhang,G.,Lin,M.,Sun,L.,etc.A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir[J].2012,157(2).
[25]Lok AS,McMahon BJ.Chronic hepatitis B: update 2009.[J].2009,50(3).